JP2023518596A5 - - Google Patents

Info

Publication number
JP2023518596A5
JP2023518596A5 JP2022558063A JP2022558063A JP2023518596A5 JP 2023518596 A5 JP2023518596 A5 JP 2023518596A5 JP 2022558063 A JP2022558063 A JP 2022558063A JP 2022558063 A JP2022558063 A JP 2022558063A JP 2023518596 A5 JP2023518596 A5 JP 2023518596A5
Authority
JP
Japan
Prior art keywords
fragment
protein
polynucleotide
split
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518596A (ja
Filing date
Publication date
Priority claimed from EP20382236.6A external-priority patent/EP3885440A1/en
Application filed filed Critical
Publication of JP2023518596A publication Critical patent/JP2023518596A/ja
Publication of JP2023518596A5 publication Critical patent/JP2023518596A5/ja
Pending legal-status Critical Current

Links

JP2022558063A 2020-03-26 2021-03-26 スプリットインテイン及びその使用 Pending JP2023518596A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382236.6 2020-03-26
EP20382236.6A EP3885440A1 (en) 2020-03-26 2020-03-26 Split inteins and their uses
PCT/EP2021/058016 WO2021191447A1 (en) 2020-03-26 2021-03-26 Split inteins and their uses

Publications (2)

Publication Number Publication Date
JP2023518596A JP2023518596A (ja) 2023-05-02
JP2023518596A5 true JP2023518596A5 (enExample) 2024-04-05

Family

ID=70292931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558063A Pending JP2023518596A (ja) 2020-03-26 2021-03-26 スプリットインテイン及びその使用

Country Status (10)

Country Link
US (1) US20230116688A1 (enExample)
EP (2) EP3885440A1 (enExample)
JP (1) JP2023518596A (enExample)
KR (1) KR20220160052A (enExample)
CN (1) CN115698307A (enExample)
AU (1) AU2021241899A1 (enExample)
BR (1) BR112022019167A2 (enExample)
CA (1) CA3175696A1 (enExample)
IL (1) IL296712A (enExample)
WO (1) WO2021191447A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019336245B2 (en) 2018-09-07 2026-02-26 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
CA3152679A1 (en) * 2019-08-28 2021-03-04 The Trustees Of Princeton University Atypical split inteins and uses thereof
CN116096905A (zh) 2020-02-21 2023-05-09 阿库斯股份有限公司 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法
EP4424714A4 (en) * 2021-10-29 2025-10-15 Shanghai Sinobay Biotechnology Co Ltd Condition-Controlled Splicable Chimeric Antigen Receptor Molecule and Its Use
EP4527933A4 (en) * 2022-05-17 2025-12-24 Eye & Ent Hospital Of Fudan Univ DUAL-SUPPORT SYSTEM FOR THE TREATMENT OF HEARING LOSS, AND ITS USE
KR20250141200A (ko) * 2023-02-01 2025-09-26 알렌 인스티튜트 전압-게이팅 나트륨 채널 기능의 인테인 매개 재구성
WO2024251077A1 (zh) 2023-06-07 2024-12-12 北京中因科技有限公司 表达盒组合及其应用
WO2025038955A1 (en) * 2023-08-16 2025-02-20 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Systems and methods for improving safety of split intein aav mediated gene therapy
AU2024338787A1 (en) 2023-09-04 2026-03-19 Splicebio, Sl Use of split intein for the treatment of scn1a associated disease
WO2025153705A1 (en) 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector
WO2026013288A1 (en) 2024-07-12 2026-01-15 Splicebio, Sl Split intein for use in the treatment of cep290-associated disease
WO2026057767A1 (en) 2024-09-13 2026-03-19 Splicebio, Sl Use of split intein for the treatment of abca3-associated disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO2007127428A2 (en) 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US20180327779A1 (en) * 2015-03-03 2018-11-15 Fondazione Telethon (IT/IT) Multiple vector system and uses thereof
US11203621B2 (en) * 2015-06-19 2021-12-21 Riken PH-responsive proteolysis probe
WO2017132580A2 (en) * 2016-01-29 2017-08-03 The Trustees Of Princeton University Split inteins with exceptional splicing activity
JP2022512718A (ja) * 2018-10-15 2022-02-07 フォンダッツィオーネ・テレソン インテインタンパク質及びその使用

Similar Documents

Publication Publication Date Title
JP2018537087A5 (enExample)
JP2018171063A5 (enExample)
JP2023506765A5 (enExample)
JP2019506166A5 (enExample)
JP2019122392A5 (enExample)
JP2023504914A5 (enExample)
JP2011501951A5 (enExample)
JP2023528207A5 (enExample)
JP2012505902A5 (enExample)
EP3960756A1 (en) Flagellin fusion protein and use thereof
JP2014500724A5 (enExample)
DK2190863T3 (en) New albumin binding compositions, methods and uses
JP2013517783A5 (enExample)
CA2901368A1 (en) Csf1 therapeutics
JP2023553697A5 (enExample)
JP2020517260A5 (enExample)
JP2023525752A5 (enExample)
JP2024508683A5 (enExample)
JP2023512824A5 (enExample)
Li et al. A novel method for purifying recombinant human host defense cathelicidin LL-37 by utilizing its inherent property of aggregation
JP2023545707A5 (enExample)
JP2020509737A5 (enExample)
JP2012516140A5 (enExample)
CN104844712A (zh) 肺炎链球菌蛋白抗原及其制备方法和应用
CN105658228B (zh) 结合人类补体c5的稳定多肽